Company / Capital Expenditures
NOVAVAX INC Capital Expenditures History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$54.5M
FY2022
5-year range
$54.5M / $57.5M
FY2018-FY2022
Trend
-5.2%
vs FY2021
Sector context
#27 of 194
Health Care
What the data says
NOVAVAX INC's capital expenditures of $54M is higher than 86% of companies in the Health Care sector (FY2022). Capital Expenditures has fluctuated over the past 7 years, ranging from $4M in FY2019 to $57M in FY2021.
Based on SEC 10-K filings.
$54M in FY2022 with a 5-year CAGR of +24.4%. Top quartile in the Health Care sector.
Remained stable around $54M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +135.2%
- 5-Year CAGR
- +24.4%
- 10-Year CAGR
- -
Sector benchmark
-53.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +24.4%, indicating consistent growth.
- In FY2022, capital expenditures decreased 5.2% year-over-year.
- Ranks #27 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.87 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.5%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $54.5M | -5.2% |
| FY2021 | $57.5M | +5.2% |
| FY2020 | $54.6M | +1203.9% |
| FY2019 | $4.2M | -77.0% |
| FY2018 | $18.2M | -0.4% |
| FY2017 | $18.3M | +151.3% |
| FY2016 | $7.3M | +25.6% |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026